Anti-Human MCAM/CD146 Reference Antibody (JM1-24-3, RUO)

Catalog No.	HW484046
Brand	abinScience
Host species	Human
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS pH 7.4
Purity	>95% purity as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target	CD146, Melanoma cell adhesion molecule, S-endo 1 endothelial-associated antigen, Melanoma-associated antigen A32, MUC18, MCAM, Melanoma-associated antigen MUC18, Cell surface glycoprotein MUC18, Cell surface glycoprotein P1H12
References	1. Feng R, et al. Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma. J Exp Clin Cancer Res. 2020;39(1):273. Published 2020 Dec 5. [HW484046] 2. Zhang F, et al. MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma. J Transl Med. 2025;23(1):473. Published 2025 Apr 24. [HW484046]
Purification	Protein A/G purified from cell culture supernatant.
Biological activity	JM1-24-3 (0.001-10 ug/mL) binds dose-dependently to live A375, A2058, and WM266-4 melanoma cells, with significantly stronger binding to highly metastatic A2058 and WM266-4 cells than to low metastatic A375 cells [1]. JM1-24-3 (0.001-10 ug/mL) binds dose-dependently to A375, A2058, and WM266-4 melanoma cell lysates, with significantly stronger binding to highly metastatic A2058 cell lysates than to WM266-4 or low metastatic A375 cell lysates [1]. JM1-24-3 binds to recombinant MUC18 with a high affinity (K D = 1.60E-09) [1]. JM1-24-3 (0.001-1 ug/mL) binding to WM266-4 melanoma cells is partially dependent on N-linked glycosylation of MUC18, as tunicamycin treatment (3.0 ug/mL; 24 h) reduces binding by 40.7% [1]. JM1-24-3 (1 h, 6 h for RPPA; 0.5-24 h for WB) binding to MUC18 on WM266-4 melanoma cells modulates downstream signaling pathways, including time-dependent reduction of p-AKT (Ser473) and p-mTOR (Ser2448) phosphorylation, and alters expression of key cancer-associated proteins [1]. JM1-24-3 (150 ug/mL; 7 days) inhibits proliferation of A375, A2058, and WM266-4 melanoma cells by 52%, 76%, and 46% respectively after 7 days of incubation [1]. JM1-24-3 (150 ug/mL; 24 h) inhibits migration of WM266-4 melanoma cells by 58% after 24 h of incubation [1]. JM1-24-3 (150 ug/mL) inhibits invasion of WM266-4 melanoma cells by 52% [1]. Cell Proliferation Assay [1] Cell Line: A375, A2058, WM266-4 Concentration: 150 ug/mL Incubation Time: 7 days Result: Significantly inhibited proliferation of all three cell lines: A375 by 52%, A2058 by 76%, and WM266-4 by 46% (p < 0.01 for all) compared to irrelevant mAb treatment. Cell Migration Assay [1] Cell Line: WM266-4 Concentration: 150 ug/mL Incubation Time: 24 h Result: Significantly reduced WM266-4 cell migration by 58% (p < 0.01) compared to irrelevant mAb treatment. JM1-24-3 (6 mg/kg; i.p.; twice weekly; for 45 days) significantly reduces the volume of subcutaneous melanoma xenografts, with no observed toxicity [1].
Endotoxin level	< 10 EU/mg
Expression system	Mammalian cells
Accession	P43121
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative name	JM1-24-3
Clone ID	JM1-24-3
Note	For research use only. Not suitable for clinical or therapeutic use.